Vivekanand Ankush Kashid

Dr. Vivekanand Ankush Kashid

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
DSDisha D. Shah
Disha D. Shah
MCMehul R Chorawala
Mehul R Chorawala
NRNeha Raghani
Neha Raghani
RPRajanikant Patel
Rajanikant Patel
MFMohammad Fareed
Mohammad Fareed
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati

21 August 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Manickam RajkumarManickam Rajkumar
Manickam Rajkumar
NPNadarajan Prathap
Nadarajan Prathap
VKVivekanand Ankush Kashid
Vivekanand Ankush Kashid
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
KPKokila Palani
Kokila Palani
BBBiswajit Basu
Biswajit Basu
Mesoporous silica nanoparticles (MSNs) have emerged as versatile nanocarriers for biomedical applications because of their unique physicochemical properties, including high surface area, large pore volume, excellent drug-loading capacity, controllable biodegradation, and facile surface functionalization. These characteristics have enabled the development of advanced drug delivery systems with enhanced therapeutic efficacy, targeted delivery, improved bioavailability, and reduced systemic toxicity. Recent advances in MSN synthesis, physicochemical properties, surface engineering, and functionalization strategies have significantly improved their biological performance and therapeutic potential. In particular, integrating polymers, lipids, and liposomes with MSN platforms has enhanced colloidal stability, circulation time, cellular uptake, and target specificity, thereby facilitating efficient, stimuli-responsive drug delivery. This review highlights MSN-based drug delivery systems in cancer therapy, where multifunctional nanocarriers enable site-specific delivery, controlled drug release, enhanced tumor accumulation, and reduced off-target effects. The review discusses the expanding roles of MSNs in antimicrobial therapy, wound healing, tissue engineering, and regenerative medicine, emphasizing their ability to promote localized therapeutic delivery, immunomodulation, angiogenesis, and tissue regeneration. The review discusses the diagnostic and theragnostic capabilities of MSNs for disease imaging and monitoring. It also critically evaluates current challenges related to biocompatibility, biodegradation, toxicity, biological barriers, large-scale manufacturing, clinical translation, and regulatory considerations. This review provides a comprehensive overview of recent progress, current limitations, and future opportunities for MSN-based platforms in targeted drug delivery and advanced biomedical applications, supporting their continued advancement toward clinical translation and precision medicine.

1 January 2025
Verified
Journal Article
Open access
PDF file
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween
RBRamenani Babu
Ramenani Babu
VKVivekanand Ankush Kashid
Vivekanand Ankush Kashid
AGAbhilasha Gupta
Abhilasha Gupta
MHMohammed Haneefa
Mohammed Haneefa
VBVivekanand Babu
Vivekanand Babu
Objective: To design and develop sustained-release (SR) glimepiride implants enabling long-term glycemic control with minimized burst release and improved adherence. Methods: Biodegradable PLGA-based in situ forming implants were engineered with solvent-induced phase inversion, using N-methyl-2-pyrrolidone as the primary solvent and polyethylene glycol as a plasticizer to modulate matrix porosity and initial drug efflux. A response-surface design optimized polymer concentration, plasticizer level, and co-solvent ratio to balance burst control and sustained kinetics. Formulations were characterized by SEM, in vitro release profiling over 28 days, and in vivo pharmacokinetics/pharmacodynamics in diabetic rodent models versus oral glimepiride. Results: Increasing PLGA and PEG content reduced surface porosity and attenuated the initial burst while sustaining release, achieving near-zero-order kinetics post-induction. Optimized implants curtailed 2–24h burst and provided depot activity for up to 14 days in vivo, maintaining plasma levels comparable to safe exposures from marketed tablets while prolonging glucose-lowering effects. Embedding glimepiride in nanoparticulate/triblock matrices within PLGA systems further refined release control and depot performance. Design principles and strategies align with contemporary advances in PLGA implant engineering to mitigate burst and enhance completeness of release. Conclusion: Glimepiride SR implants based on optimized PLGA in situ systems offer a feasible depot approach for extended glycemic control, with controlled burst, sustained therapeutic exposure, and potential to improve adherence and outcomes in type 2 diabetes.

Verified
Journal Article
Open access
PDF file
AMArathy S Mohan
Arathy S Mohan
NJNARAYANAN J
NARAYANAN J
VKVivekanand Ankush Kashid
Vivekanand Ankush Kashid
RPRavish J. Patel
Ravish J. Patel
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Major depressive disorder (MDD) is a heterogeneous psychiatric disorder characterized by impaired mood, neuroplasticity, neuroinflammation, and dysregulated stress response systems. Chronic stress can induce epigenetic changes leading to depression. Evidence suggests that histone acetylation and deacetylation are epigenetic processes involved in changes in gene expression. Histone deacetylases (HDACs) modulate chromatin structure and transcription, and their dysregulation is associated with stress susceptibility, decreased brain-derived neurotrophic factor (BDNF) signaling, impaired synaptic plasticity, and inflammatory activation. HDAC isoforms HDAC3 and HDAC6 have emerged as epigenetic regulators in stress-induced depression. HDAC3 is a transcriptional regulator involved in neuroplasticity-related gene expression, inflammatory signaling, and glucocorticoid receptor-mediated stress responses. In contrast, HDAC6 is cytoplasmic and regulates non-histone substrates involved in microtubule dynamics, synaptic function, protein trafficking, and the regulation of the hypothalamic–pituitary–adrenal axis (HPA axis). Preclinical studies show that HDAC3 or HDAC6 inhibition can exert antidepressant-like effects by promoting neuroplasticity, reducing neuroinflammation, and restoring stress-related signaling. Dual targeting is an interesting therapeutic approach because both regulate complementary mechanisms. However, clinical translation is limited by poor blood–brain barrier penetration, systemic toxicity, insufficient isoform selectivity, and a lack of clinical evidence. This review summarizes the roles and mechanisms of HDAC3 and HDAC6, the rationale for dual targeting, translational limitations, and future therapeutic perspectives.

8 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMArjun Gokulan M
Arjun Gokulan M
NJNARAYANAN J
NARAYANAN J
VKVivekanand Ankush Kashid
Vivekanand Ankush Kashid
RPRavish J. Patel
Ravish J. Patel
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
In the present era, modern drug delivery systems play a fundamental role in ensuring the systematic delivery of the drug into the body, reaching the desired targets. Across recent decades, the drug delivery system has evolved from simple oral and injectable formulations to interpolating with various developed techniques to fabricate innovative treatment approaches for safer, effective, and better patient compliance. Progressive techniques like nanoparticles, microparticles, liposomes, polymer-based systems, 3D printing, and biological carriers have been extensively combined with specifically targeted drug-delivery techniques across infectious, oncological, pulmonary, and neurological conditions. Microneedle transdermal patches have advanced in tandem. They have gained attention for their advancement to surpass the stratum corneum, minimal invasiveness, independent delivery, and patient compliance. This review provides a translational perspective by integrating MN materials and device engineering with drug-delivery performance, patient usability, clinical evidence, manufacturing scalability, and regulatory considerations to examine the progression of MN technologies from laboratory development toward real-world healthcare implementation. Microneedles are fabricated in different types, such as solid, coated, hollow, dissolving, and hydrogel-based, to enhance precision in dosing, better permeability, and suitability across diverse populations, and complex molecules are designed, such as proteins, peptides, hormones, vaccines, and cosmetic agents. Moreover, studies suggest MN are widely accepted by geriatric and pediatric groups, reduce anxiety, and significantly benefit individuals with trypanophobia, swallowing difficulties in the case of oral doses, and compromised venous action, in addition to breaking social inequity. MN-induced microchannels can transiently increase skin permeability and may facilitate sustained or controlled drug delivery depending on MN geometry, formulation, application conditions, skin site, and individual skin characteristics. The persistence of these microchannels and their safety profile are dependent on both device and formulation characteristics. MN is a pivotal part of the novel drug delivery system, addresses the complications arising due to conventional drug delivery, and proves to focus on the improvement of pharmacokinetic parameters, patient-centric therapy, target delivery, and real-world accessibility. Further transformation in the enhancement of MN technology can lead to clinically promising drug delivery systems for the management of long-term treatment and boost next-generation therapies.